{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:49:39Z","timestamp":1791308979726,"version":"4.3.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/inf.0000000000000243","type":"journal-article","created":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T08:16:55Z","timestamp":1388564215000},"page":"600-605","source":"Crossref","is-referenced-by-count":22,"title":["Neonatal Vancomycin Continuous Infusion"],"prefix":"10.1097","volume":"33","author":[{"given":"Amanda","family":"Gwee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Cranswick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Coghlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope A.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210202","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1128\/AAC.30.6.823","article-title":"Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies.","volume":"30","author":"Foster","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-12-20210202","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R3-12-20210202","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","article-title":"Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study.","volume":"45","author":"Wysocki","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-12-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis.","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R5-12-20210202","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00003088-200443070-00001","article-title":"Vancomycin: pharmacokinetics and administration regimens in neonates.","volume":"43","author":"de Hoog","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R6-12-20210202","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/archdischild-2012-303197","article-title":"Continuous infusion of vancomycin in neonates.","volume":"98","author":"Patel","year":"2013","journal-title":"Arch Dis Child"},{"key":"R7-12-20210202","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/archdischild-2012-302765","article-title":"Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.","volume":"98","author":"Zhao","year":"2013","journal-title":"Arch Dis Child"},{"key":"R8-12-20210202","doi-asserted-by":"crossref","first-page":"F365","DOI":"10.1136\/adc.2010.196402","article-title":"Vancomycin prescription in neonates and young infants: toward a simplified dosage.","volume":"96","author":"Oudin","year":"2011","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R9-12-20210202","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2125.1998.00763.x","article-title":"Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.","volume":"46","author":"Pawlotsky","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R10-12-20210202","doi-asserted-by":"crossref","first-page":"F418","DOI":"10.1136\/adc.2007.128280","article-title":"Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.","volume":"93","author":"Plan","year":"2008","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R11-12-20210202","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R12-12-20210202","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R14-12-20210202","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00006454-198605000-00006","article-title":"Vancomycin pharmacokinetics in infants: relationships to indices of maturation.","volume":"5","author":"Schaible","year":"1986","journal-title":"Pediatr Infect Dis"},{"key":"R15-12-20210202","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"R16-12-20210202","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1203\/00006450-198709000-00024","article-title":"The clinical pharmacology of vancomycin in seriously ill preterm infants.","volume":"22","author":"Reed","year":"1987","journal-title":"Pediatr Res"},{"key":"R17-12-20210202","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1469-0691.2005.01306.x","article-title":"Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.","volume":"12","author":"Kitzis","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"R18-12-20210202","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1128\/JCM.41.10.4660-4665.2003","article-title":"Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri.","volume":"41","author":"Center","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R19-12-20210202","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R20-12-20210202","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","article-title":"Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.","volume":"32","author":"Frymoyer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R21-12-20210202","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure.","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R22-12-20210202","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/01.CCM.0000178180.61305.1D","article-title":"Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides.","volume":"33","author":"Rello","year":"2005","journal-title":"Crit Care Med"},{"key":"R23-12-20210202","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00006454-199301000-00026","article-title":"Vancomycin-associated shock in neonates.","volume":"12","author":"Anglada","year":"1993","journal-title":"Pediatr Infect Dis J"},{"key":"R24-12-20210202","first-page":"27","article-title":"Safety of vancomycin with or without gentamicin in neonates.","volume":"12","author":"Linder","year":"1993","journal-title":"Neonatal Netw"},{"key":"R25-12-20210202","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.siny.2012.10.003","article-title":"Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration.","volume":"18","author":"Jacqz-Aigrain","year":"2013","journal-title":"Semin Fetal Neonatal Med"},{"key":"R27-12-20210202","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/jac\/dks510","article-title":"Stability and compatibility of vancomycin for administration by continuous infusion.","volume":"68","author":"Raverdy","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R28-12-20210202","first-page":"2054","article-title":"Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration.","volume":"50","author":"Szof","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"R29-12-20210202","first-page":"1729","article-title":"Stability of vancomycin hydrochloride in 5 dextrose and 0.9 sodium chloride injections.","volume":"43","author":"Gupta","year":"1986","journal-title":"Am J Hosp Pharm"},{"key":"R30-12-20210202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/014860718901300163","article-title":"Stability and delivery of vancomycin hydrochloride when admixed in a total parenteral nutrition solution.","volume":"13","author":"Schilling","year":"1989","journal-title":"JPEN J Parenter Enteral Nutr"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:02:46Z","timestamp":1620954166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201406000-00012"}},"subtitle":["Still a Confusion?"],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000243","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}